Reports Q2 revenue $33.31M, consensus $31.21M. “I am pleased with the over 30% U.S. revenue growth in the second quarter of 2023, led by increasing demand for our solutions. Having consistently delivered several consecutive quarters of record revenue and operating leverage, we are excited about the significant opportunity ahead of us as we capitalize on underlying business momentum and progress towards profitability,” said Laura Francis, CEO of SI-BONE, Inc. “As we look beyond 2023, we are focused on judiciously investing in long-term growth drivers, including portfolio expansion programs as well as physician engagement initiatives to extend our market leadership and build a sustainable and high-growth revenue platform.”
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on SIBN:
- SI-BONE, Inc. Reports Financial Results for the Second Quarter 2023 and Increases Annual Guidance
- Si-Bone (SIBN) Q2 Earnings Cheat Sheet
- SI-BONE to Present at Canaccord Genuity 43rd Annual Growth Conference on August 9, 2023
- SI-Bone price target raised to $33 from $28 at Truist
- SI-BONE To Report Second Quarter 2023 Financial Results on August 7, 2023